Simulation-free vaginal brachytherapy produced low five-year recurrence in high-intermediate-risk endometrial cancer
Five-year vaginal recurrence was 3.6% without verification imaging, versus 1.6% reported in the separate PORTEC-4a brachytherapy cohort.